Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 65 Neoplasms 29 Neoplasm Metastasis 11 Thyroid Neoplasms 10 Thyroid Carcinoma, Anaplastic 9 Glioma 9 Brain Neoplasms 9 Multiple Myeloma 7 Colorectal Neoplasms 7 Carcinoma, Non-Small-Cell Lung 7 Hematologic Neoplasms 6 Thyroid Cancer, Papillary 4 Skin Neoplasms 4 Ameloblastoma 4 Histiocytosis, Langerhans-Cell 3 Glioblastoma 3 Astrocytoma 3 Rectal Neoplasms 2 Prostatic Neoplasms 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Oligodendroglioma 2 Neurofibroma, Plexiform 2 Neurocytoma 2 Neuroblastoma 2 Lymphoma, Non-Hodgkin 2 Lymphoma 2 Lung Neoplasms 2 Ganglioneuroma 2

Interventions

Doxorubicin 141 Ifosfamide 85 Radiotherapy 80 Cyclophosphamide 72 Gemcitabine 63 Filgrastim 54 pembrolizumab 43 pazopanib 39 Etoposide 39 Docetaxel 39 Vincristine 37 Cisplatin 35 Trabectedin 32 Nivolumab 32 Irinotecan 26 Magnetic Resonance Spectroscopy 25 Carboplatin 25 Temozolomide 23 Ipilimumab 22 Bevacizumab 20 Radiation 19 Surgical Procedures, Operative 18 Granulocyte Colony-Stimulating Factor 18 Sirolimus 17 Mesna 17 Melphalan 17 Dactinomycin 17 Biopsy 17 eribulin 16 anlotinib 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Sarcoma × dabrafenib × Clear all

NCT03784014 2026-04-29

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Completed

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡